John Lansing's Trending123
John Lansing's Trending123
Username: Password: Login
Trade Talk E-Letter Products & Services Trading Tools Portfolios Members Home

Stock Sectors

(Click sector to view stock chart)

Research Services

Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)


Spire Corporation engages in the development, manufacture, and marketing of biomedical, solar equipment, solar systems, and optoelectronics products in the United States. It provides surface treatments to manufacturers of orthopedic and other medical devices in the biomedical area; develops and markets hemodialysis catheters and related devices for the treatment of chronic kidney disease; and performs sponsored research programs into practical applications of biomedical and biophotonic technologies. The company develops, manufactures, and markets specialized equipment for the production of terrestrial photovoltaic modules from solar cells, as well as provides custom and building integrated photovoltaic modules, stand-alone emergency power back up, and electric power grid-connected distributed power generation systems. Spire also provides custom compound semiconductor foundry and fabrication services to customers involved in biomedical/biophotonics instruments, telecommunications, and defense applications. In addition, it offers various services, including compound semiconductor wafer growth, other thin film processes, and related device processing and fabrication, as well as provides materials testing services and performs services in support of sponsored research into practical applications of optoelectronic technologies. The company was founded by Roger G. Little. Spire was incorporated in 1969 and is headquartered in Bedford, Massachusetts.


Albany Molecular Research, Inc. operates as a chemistry-based drug discovery and development company. It develops small molecule prescription drugs. Albany offers drug lead discovery, medicinal chemistry, chemical development, and analytical chemistry services. The company conducts research and development projects; and collaborates with various pharmaceutical, biotechnology, and genomics companies. It also provides discovery technologies, including isolation, purification, structure elucidation, and sample collection libraries from microbial and botanical sources, computational chemistry, virtual screening, microbiology, fermentation, asymmetric synthesis, and high throughput metabolic screening. The company offers its services to pharmaceutical companies, biotechnology companies, agricultural companies, fine chemical companies, and contract chemical manufacturers. Albany Molecular Research was founded in 1991 and is based in Albany, New York.


PharmaNet Development Group, Inc., a drug development services company, provides clinical drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies worldwide. The company operates in two segments, Early Stage Clinical Development and Late Stage Clinical Development. The Early Stage Clinical Development segment provides bioequivalency clinical trials, bioanalytical services, and support services. It operates Phase I clinical trial facilities in Quebec City, Canada which has 164 beds; and Montreal, Canada which has 150 beds. This segment also operates five bioanalytical laboratories in Philadelphia, Pennsylvania; Princeton, New Jersey; Quebec City and Toronto, Canada; and Barcelona, Spain. The Late Stage Clinical Development segment provides Phase II through Phase IV services, including data management and biostatistics, medical and scientific affairs, regulatory affairs and submissions, clinical information technology services, and consulting services. It conducts clinical trials in oncology, neurosciences, cardiovascular, and infectious diseases. The company also offers Web-based products that support clinical development activities. PharmaNet Development Group was founded in 1984. It was formerly known as SFBC International, Inc. and changed its name to PharmaNet Development Group, Inc. in 2006. The company is headquartered in Princeton, New Jersey.


ICON public limited company, a contract research organization, provides clinical research and development services to the pharmaceutical, biotechnology, and medical device industries worldwide. Its services include clinical pharmacology, bioanalysis, pharmacokinetic and pharmacodynamic analysis, study protocol preparation, case report form preparation, clinical trial approvals, investigator recruitment, study monitoring and data collection, patient safety monitoring, clinical data management, biostatistical services, medical reporting, central laboratory services, interactive voice response, animal health, regulatory consultancy, and strategic drug development services. The company also provides digital imaging services, such as centralized management, processing, and reading of digitized medical images generated in clinical trials, including X-ray, MRI, CT, PET, Nuclear Medicine, and Ultrasound. As of August 31, 2005, it operated in 37 locations in 23 countries. The company was founded by John Climax and Ronan Lambe in 1990 and is headquartered in Dublin, Ireland.


Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid probe-based products for the clinical diagnosis of human diseases, and for the screening of donated human blood. It markets a portfolio of products that use company's technologies to detect various infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia, and fungal infections. The company also offers blood-screening assays for the simultaneous detection of human immunodeficiency virus (type 1), hepatitis C virus, and hepatitis B virus presence. In addition, Gen-Probe offers TIGRIS DTS instrument that is used for investigational use in blood screening applications in the United States. The company markets its products to various customers, such as reference laboratories, public health laboratories, and hospitals in North America, Europe, and Japan. It has strategic alliance agreements with Chiron Corporation and Bayer Corporation, as well as has licensing agreements with Corixa Corporation, AdnaGen AG, DiagnoCure, Vysis, Inc., and Organon Teknika B.V. The company also has a collaboration agreement with GE Infrastructure Water and Process Technologies, and Millipore Corp. for developing, manufacturing, and commercializing nucleic acid testing technologies. Gen-Probe Incorporated was founded by David E. Kohne, Thomas H. Adams, and Howard C. Birndorf in 1983. The company is headquartered in San Diego, California.


CLEVELAND BIOLABS, INC. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins in the United States. Its products in development include Protectans, the modified proteins of microbes that protect cells from apoptosis; and Curaxins, the small molecules that destroy tumor cells by simultaneously targeting two regulators of apoptosis. The company's lead product candidates, CBLB502 showed radioprotective efficacy as a single therapy in non-human primates; and Protectan CBLB612 provided protection in a mouse model from lethal hematopoietic-induced radiation sickness. In addition, it is developing Curaxin CBLC102, a Phase II clinical trial product, for the treatment of hormone refractory prostate cancer. CLEVELAND BIOLABS has a collaboration agreement with Cleveland Clinic Foundation to use Cleveland Clinic's research base underlying the company's therapeutic platform; strategic research partnership with Roswell Park Cancer Institute to develop its cancer and radioprotectant drug candidates; and strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds, and jointly manage the development and commercialization of compounds arising from selected projects. The company was founded in 2003 and is headquartered in Buffalo, New York.


Cytomedix, Inc., a development stage biotechnology company, engages in developing, producing, and licensing autologous cellular therapies for the treatment of chronic nonhealing wounds using its propriety platelet gel and related product therapies. It offers the AutoloGel System to produce the platelet rich plasma gel for the treatment of chronic, nonhealing wounds. The company primarily distributes its products through a network of commission-based independent sales representatives. Cytomedix was founded by Charles Worden. The company was founded in 1987 and is headquartered in Rockville, Maryland.


Parexel International Corporation, a biopharmaceutical services company, provides clinical research, medical marketing, consulting, and informatics and advanced technology products and services to pharmaceutical, biotechnology, and medical device industries worldwide. The company operates through three segments: Clinical Research Services, PAREXEL Consulting and Medical Marketing, and Perceptive. The Clinical Research Services segment offers clinical trials management and biostatistics, data management, and clinical pharmacology, as well as related medical advisory and investigator site services. It provides these services in cardiology, oncology, infectious diseases, neurology, allergy/immunology, endocrinology/metabolism, gastroenterology, obstetrics/gynecology, orthopedics, pediatrics, psychiatry, and transplantation areas. The PAREXEL Consulting and Medical Marketing segment offers drug development, regulatory, manufacturing compliance, business process consulting, staffing solutions, and marketing expertise consultation to the pharmaceutical, biopharmaceutical, and medical device industries in the United States, Europe, and Asia. The Perceptive segment offers a portfolio of products and services that include medical imaging services, interactive voice response systems, clinical trials management systems, Web-based portals, systems integration, and patient diary applications. PAREXEL was founded by Josef H. von Rickenbach in 1983. The company is headquartered in Waltham, Massachusetts.


Covance, Inc. operates as a drug development services company. It offers a range of early stage and late stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries worldwide. The company also offers laboratory testing services to the chemical, agrochemical, and food industries. Covance offers a range of early development services, including preclinical and Phase I clinical service offerings that involve toxicology services, pharmaceutical chemistry, and bioanalytical and related services. Its late-stage development services include central laboratory services, clinical development services, periapproval services, central electrocardiogram diagnostic services, and healthcare economic and reimbursement services. Covance was founded in 1987 and is headquartered in Princeton, New Jersey.


Commonwealth Biotechnologies, Inc. engages in the research and development of contract biotechnology research services to government, industry, and academia. It offers a range of services relating to design, synthesis, purification, and analysis of peptides, proteins, and oligonucleotides, as well as creates assay and detection methods. The company's services include DNA analyses, genomics, proteomics, biochemical analyses, mass spectral analysis, microbiological services, pathogen testing, food microbiology, peptide services, protein sequencing, and drug discovery. In addition, Commonwealth Biotechnologies provides genetic identity testing, including paternity, forensic, and combined DNA index system analyses. Its customers primarily include pharmaceutical industry researchers and government sponsors of research, including agencies of the Department of Defense in the United States. The company was founded in 1992 and is based in Richmond, Virginia.


Acacia Research Corporation - Acacia Technologies engages in the development, acquisition, and license of patented technologies in the United States. It owns and out-licenses a portfolio of U.S. and foreign patents covering digital audio and video transmission and receiving systems, commonly known as audio-on-demand, video-on-demand, and audio/video streaming. The Acacia Technologies group owns and out-licenses patented technology known as the V-chip to consumer electronics manufacturers. The company's patented proprietary digital media transmission technology enables the digitization, encryption, storage, transmission, receipt, and playback of digital content via various means. These include cable TV, which comprises digital ad insertion and video-on-demand programming; satellite TV programming; and the Internet, which includes distance learning and other Internet programming comprising digital audio/video content, wireless delivery of video content, fiber-optic delivery of video content, and hotel in-room digital delivery of programming. The company is headquartered in Mukilteo, Washington.


The Advisory Board Company (TABC) provides best practices research and analysis to the healthcare industry in the United States. Best practices research identifies, analyzes, and describes specific management initiatives, strategies, and processes to solve common problems or challenges. The company offers various programs that provide members with assistance in addressing strategic issues, operational issues, or management issues. Its research managers and analysts conduct interviews with health care industry executives on various topics, including health care industry strategy, health care marketing, revenue management and product line development, health system cost reduction and clinical reform, hospital department operations, and pharmaceuticals and medical device technology, as well as nursing recruitment, retention, and productivity. As of March 31, 2005, TABC offered 25 membership programs; and its membership consisted of approximately 2,500 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device and supply companies The company was founded in 1979 by David G. Bradley and is headquartered in Washington, D.C.


Luna Innovations Incorporated engages in the research, development, and commercialization of technologies in the areas of molecular technology solutions and sensing solutions. The company operates through two divisions, Technology Development and Products. The Products division offers instrumentation and test and measurement products, and healthcare products. Its test and measurement products measure the integrity, quality, and efficacy of fiber optic network components and subassemblies, designed for manufacturers and suppliers of optical components and sub-assemblies. The company offers Optical Vector Analyzer platform for manufacturers and suppliers of optical components and sub-assemblies; Optical Backscattering Reflectometer, a sensitive diagnostic device for data and telecommunications companies and the service providers, who maintain their own fiber optic networks; and distributed sensing systems, which are products comprising multiple sensors, whose input is integrated through a fiber optic network and software; and a line of swept tunable lasers. It also develops various devices that use high frequency sound, or ultrasonic, waves to evaluate the physical properties of materials for use in non-destructive industrial testing and homeland security applications; products for remote and secure asset monitoring applications. The company's healthcare products include Emboli Detection and Classification QUANTIFIER product, a noninvasive medical device that uses quantitative ultrasound technology to count emboli in ex-vivo blood circuits in real-time; and Emergency Non-Invasive Tissue and Compartment Testing product for detecting compartment syndrome; nanomaterial-based medical products, including Trimetasphere nanomaterials. The Technology Development division provides applied research services to government and corporate customers. The company was incorporated in 1990 and is headquartered in Roanoke, Virginia.


PRA International operates as a contract research organization providing product development services for pharmaceutical and biotechnology companies worldwide. The company's services include data management, statistical analysis, clinical trials management, and regulatory and drug development consulting services. Its clinical development services include, creating drug development and regulatory strategy plans; executing Phase I clinical trials; performing Phase II through IV multicenter and international clinical trials; developing and analyzing integrated global clinical databases; preparing and submitting regulatory filings; and managing long-term drug safety programs. PRA International operates in North America, Europe, Africa, South America, Australia, and Asia. The company, formerly known as PRA Holdings, Inc., was founded in 1976. PRA International is headquartered in Reston, Virginia.


Arbitron, Inc. operates as a media and marketing research firm serving radio broadcasters, radio networks, cable companies, advertisers, advertising agencies, and outdoor advertising companies, as well as the online radio industry in the United States, Mexico, and Europe. It measures radio audiences across the United States; measures national radio audiences, and the audience size of network radio programs and commercials; provides application software used for accessing and analyzing media audience and marketing information data; and provides consumer and media usage information services to radio, cable television, advertising agencies, advertisers, outdoor and out-of-home media, and Internet broadcasters, as well as broadcast television and print media services. The company, Through Scarborough Research joint venture with VNU, Inc., also provides media and marketing research services to the broadcast television, magazine, newspaper, and online industries. Arbitron was founded in 1912 and is headquartered in New York City.


National Research Corporation provides ongoing survey-based performance measurement, analysis, tracking, and improvement services to the healthcare industry. The company addresses healthcare organizations' need to track their performance at the enterprise-wide, departmental, and physician/caregiver levels. It develops tools that enable healthcare organizations to obtain performance measurement information necessary to improve their business practices. The company also focuses on the information needs of the healthcare industry. Its information services include renewable performance tracking services, custom research, educational services, and a renewable syndicated service. The company provides market research services to hospitals and insurance companies. National Research was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, Nebraska.


National Technical Systems, Inc. (NTS) operates as a services company that supplies technical services and solutions to various industries, including aerospace, defense, transportation, electronics, power, computers, and telecommunications. NTS, utilizing its various testing facilities, staffing solutions, and certification services, enables its customers sell their products in world markets. The company operates in two segments, Engineering and Evaluation, and Technical Solutions. The Engineering and Evaluation segment provides trained technical personnel for product certification, product safety testing, and product evaluation. In addition, this segment performs management registration and certification services to International Organization for Standardization-related standards. The Technical Solutions segment provides technical experts for engineering and information technology services. This segment also supports its clients in sourcing and identifying candidates for direct hire. The company serves its customers through its facilities located in the United States, Canada, Germany, Japan, and Vietnam. NTS was founded in 1961 and is headquartered in Calabasas, California.


Landauer, Inc. provides analytical services to determine occupational and environmental radiation exposure. It offers radiation monitoring services and other services incidental to radiation dose measurement. The company manufactures various types of radiation detection monitors, distributes and collects these monitors to and from clients, and analyses and reports radiation exposure findings. It provides optically stimulated luminescent badges that are worn for a period by its customers for measuring the dosages of x-ray, gamma radiation, and other penetrating ionizing radiations. The company's other radiation measurement-related services include providing administrative and informational tools to customers for the management of their radiation safety programs. It offers its radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, and other industries in the United States, Canada, Japan, Brazil, China, the United Kingdom, Australia, and France. The company, formerly known as Tech/Ops Landauer, Inc., was founded in 1987 and changed its name to Landauer, Inc. in 1991. Landauer is based in Glenwood, Illinois.


LECG Corporation and its wholly owned subsidiary, LECG, LLC, provides expert services, including economic and financial analysis, expert testimony, litigation support, and strategic management consulting to a range of public and private enterprises. It delivers independent expert testimony, original authoritative studies, and strategic advice to legislative, judicial, regulatory, and business decision makers. The company's other service offerings include factual and statistical analyses, report preparation and presentation, and electronic discovery and data collection. It provides its services primarily in the United States and internationally in Argentina, Australia, Belgium, Canada, France, New Zealand, South Korea, Spain, and the United Kingdom. The company was co-founded in 1988 by David J. Teece and is headquartered in Emeryville, California.


Arrowhead Research Corporation, a development stage company, operates as a nanotechnology company. The company, through its subsidiary, Aonex Technologies, Inc., commercializes a method for manufacturing semiconductor nanomaterials. It develops Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers, which are nontoxic and nonimmunogenic, through its subsidiary, Insert Therapeutics, Inc. The company also conducts preclinical animal tests of IT-101, the camptothecin-Cyclosert conjugate. Arrowhead designs, develops, and commercializes novel RNA interference therapeutics to treat diseases and other medical conditions, through its subsidiary, Calando Pharmaceuticals, Inc. In addition, the company, through its subsidiary, NanoPolaris, Inc. licenses intellectual property to customers who utilize nanotube technology in their products. NanoPolaris also controls commercialization of issued patents and patent applications claiming nanotube compositions of matter and general manufacturing techniques, such as chemical vapor deposition synthesis; plasma chemical vapor deposition synthesis; and purification, solubilization, separation of certain types of tubes, coating, functionalization, and manipulation. Arrowhead was founded in 2003 and is headquartered in Pasadena, California.


Metal Storm Limited, a development stage company, engages in the research and development of electronic ballistics technology. It develops projectile launching systems utilizing electronically fired and stacked projectile technology. The company develops weapon system for unmanned ground vehicle, weapon system for unmanned aerial vehicle, fire fighting systems, and hand guns, as well as area denial weapon system and individual combat weapons. Metal Storm also manufactures and sells precision engineered parts to the defense, electronics, aircraft, and space propulsion industries. Metal Storm has an agreement with Electro Optic Systems Holdings, Ltd. to co-develop and market a new weapon system, which combines the features of Metal Storm's weapons with Electro Optic Systems fire control and sensor systems. The company was incorporated in 1994 and is headquartered in Brisbane, Australia.


Forrester Research, Inc., an independent technology research company, engages in conducting research and providing advice about the impact of technologies on business, consumers, and society. It offers a selection of products and services in the areas of Research, Data, Consulting, and Community. Research serves as the foundation of all offerings and comprises annually renewable memberships to WholeView 2 Research. Its Data products include consumer and business technographics data and services, consumer technographics omnibus survey, and custom consumer research. The company's Consulting services leverage WholeView 2 Research to deliver customized research services designed to assist clients in executing corporate strategy, promoting new initiatives, or making technology investments. Its Community products and services include annual memberships in the Forrester oval program, participation in Web site reviews and boot camps, and attendance at Forrester events. The company's WholeView Research platform combines with data, consulting, and community products and services to provide clients with access to its research, analysts, online tools, presentations, advice, and speeches. Forrester's products and services are targeted to senior management, business strategists, and marketing and technology professionals. The company sells its products and services directly through research centers and sales offices in various locations in North America, Europe, and Asia, as well as through its Web site and independent sales representatives. Forrester was founded in 1983 by George F. Colony. The company is headquartered in Cambridge, Massachusetts.


Encorium Group, Inc., a clinical research organization, engages in the design and management of clinical trials for the pharmaceutical, biotechnology, and medical device industries. The company offers various clinical research and development services supporting Phase I through Phase IV clinical trials. Its services include study protocol design; clinical trials management, such as case report form design, investigator recruitment, patient enrollment, and study monitoring and data collection; data management services; biostatistics; medical and regulatory affairs; quality assurance and compliance; report writing; and patient registries. The company offers clinical trial services across various therapeutic areas, such as cardiovascular, nephrology, endocrinology/metabolism, hematology, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, rheumatology, urology, ophthalmology, women's health, and respiratory medicine. It operates in the United States, Finland, and other parts of Europe. Encorium Group has a joint venture with Prosoft Software, Inc. to provide biostatistical, data management, and consulting services relating to clinical trial design, implementation, data analysis, and regulatory submissions. The company was founded in 1989. It was formerly known as Covalent Group, Inc. and changed its name to Encorium Group, Inc. in 2006. Encorium Group is headquartered in Wayne, Pennsylvania with additional operations in Espoo, Finland.


Maxygen, Inc., a biotechnology company, focuses on using protein optimization and modification technologies to create and develop products for human therapeutics applications. It engages in the development of novel products for the treatment and prevention of a range of diseases, such as cancer, multiple sclerosis, HIV, and hepatitis. The company's product pipeline comprises MAXY-ALPHA, an optimized interferon alpha to treat hepatitis C; MAXY-GCSF, an improved colony stimulating factor (G-CSF) to treat neutropenia; MAXY-FACTOR VII, an improved factor VII for uncontrolled bleeding indications; and MAXY-GAMMA, an optimized interferon gamma to treat idiopathic pulmonary fibrosis and other severe diseases. Maxygen also has interest in Codexis, Inc., which provides biocatalysis and fermentation processes and products to the life science and fine chemical industries. The company has strategic alliances with F. Hoffmann-La Roche, Ltd. and InterMune, Inc. Maxygen was co-founded by Russell J. Howard and Isaac Stein. The company was incorporated in 1996 and is headquartered in Redwood City, California.


Senomyx, Inc., a biotechnology company, engages in the discovery and development of flavors, flavor enhancers, and taste modulators for the packaged food and beverage industry. It primarily focus on the development of savory, sweet, and salt flavor enhancers, and bitter taste modulators. Senomyx has product, primarily flavors and flavor enhancers, discovery and development collaborations with Campbell Soup Company, The Coca-Cola Company, Kraft Foods Global, Inc., and Nestle SA. The company operates in the United States. Senomyx was founded in 1998 and is headquartered in San Diego, California.


deCODE genetics, Inc., a biopharmaceutical company, engages in the research and development of human genetics for common diseases. Its products include DG031, a phase II clinical trial completed product, which would be used for the prevention of heart attack; and DG041, a phase I clinical trial product, for atherosclerosis. The company also has target discovery programs and drug development pipeline products primarily in the areas of inflammatory, central nervous system, cancer, eye, reproductive, and metabolic. deCODE genetics has research collaboration and cross-license agreement with F. Hoffmann-La Roche for the codevelopment of inhibitors of PDE4, as well as an alliance with Merck & Co, Inc. for developing treatments for obesity. The company was co-founded by Kari Stefansson and Jeffrey Gulcher in 1996. deCODE genetics is headquartered in Reykjavik, Iceland.


Symyx Technologies, Inc. engages in the development and application of high-throughput experimentation for the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods, and automotive industries. The company operates in three segments: Collaborations, Discovery Tools, and Licensing. The Collaborations segment performs research for customers on a collaborative basis in various fields. The Discovery Tools segment provides automated instruments to pharmaceutical companies for use in pharmaceutical pre clinical testing, including preformulations, formulation, and process chemistry; and to chemical and petrochemical companies for use in catalyst discovery, optimization, and formulation. The Licensing segment consists of licensing of materials; and intellectual property, including sensors and methodology patents. The company operates in North America, Europe, Japan, and Belgium. Symyx Technologies has alliances with Exxon Mobil Corporation and Dow Chemical Company to provide research services, develop and sell discovery tools systems, and license its software and intellectual property. The company was founded by Alejandro Zaffaroni and Peter Schultz in 1994. Symyx Technologies is headquartered in Santa Clara, California.


Syntroleum Corporation engages in the research and development of a proprietary process (the Syntroleum Process) designed to convert natural gas or synthesis gas into synthetic liquid hydrocarbons, as well as in the commercialization of the Syntroleum Process. Synthetic liquid hydrocarbons produced by the Syntroleum Process are further processed, using the Syntroleum Synfining Process, into various liquid fuels, such as diesel, jet fuel, kerosene, and naphtha, as well as specialty products, such as synthetic lubricants, synthetic drilling fluid, waxes, liquid normal paraffin solvents, and certain chemical feedstocks. The company also licenses its process to others for the manufacture of fuels. Syntroleum is based in Tulsa, Oklahoma.